NYSE - Delayed Quote • USD Evolent Health, Inc. (EVH) Follow Add holdings 8.33 +0.14 +(1.71%) At close: June 6 at 4:00:02 PM EDT 8.33 0.00 (0.00%) After hours: June 6 at 4:04:18 PM EDT All News Press Releases SEC Filings 3 Stocks Under $10 in the Doghouse Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals. 3 Value Stocks Walking a Fine Line The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models. Q1 Earnings Outperformers: Phreesia (NYSE:PHR) And The Rest Of The Healthcare Technology for Providers Stocks Looking back on healthcare technology for providers stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Phreesia (NYSE:PHR) and its peers. Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Reflecting On Healthcare Technology for Providers Stocks’ Q1 Earnings: Evolent Health (NYSE:EVH) As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare technology for providers industry, including Evolent Health (NYSE:EVH) and its peers. Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit. Unpacking Q1 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks Looking back on healthcare technology stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Hims & Hers Health (NYSE:HIMS) and its peers. 1 Healthcare Stock to Keep an Eye On and 2 to Ignore Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground. Unpacking Q1 Earnings: Privia Health (NASDAQ:PRVA) In The Context Of Other Healthcare Technology for Providers Stocks Looking back on healthcare technology for providers stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Privia Health (NASDAQ:PRVA) and its peers. Healthcare Technology for Providers Stocks Q1 Earnings Review: Premier (NASDAQ:PINC) Shines As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at healthcare technology for providers stocks, starting with Premier (NASDAQ:PINC). Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Evolent Health (EVH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Evolent Health Inc (EVH) Q1 2025 Earnings Call Highlights: Strong Start with New Agreements and ... Evolent Health Inc (EVH) reports robust Q1 results, secures new contracts, and advances AI-led automation despite revenue impacts from contractual changes. Evolent Health (EVH) Q1 Earnings Lag Estimates Evolent Health (EVH) delivered earnings and revenue surprises of -33.33% and 4.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock? Evolent Health (NYSE:EVH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 37.7% below analysts’ consensus estimates. Evolent Health: Q1 Earnings Snapshot EVH) on Thursday reported a loss of $64.6 million in its first quarter. On a per-share basis, the Arlington, Virginia-based company said it had a loss of 63 cents. Earnings, adjusted for non-recurring costs and stock option expense, came to 6 cents per share. Evolent Announces First Quarter 2025 Results Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Wall Street Analysts Believe Evolent Health (EVH) Could Rally 53.33%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Evolent Health (EVH) Q1 Earnings Report Preview: What To Look For Healthcare solutions company Evolent Health (NYSE:EVH) will be announcing earnings results tomorrow after market close. Here’s what investors should know. 1 Unprofitable Stock Worth Investigating and 2 to Question Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Performance Overview Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) Return EVH S&P 500 (^GSPC) YTD -25.96% +2.02% 1-Year -64.33% +12.09% 3-Year -72.58% +45.59%